UA5980A1 - Спосіб одержання сульфаілзаміщаних похідних фенетіламіна, а також їх кислотно-адитивних солей - Google Patents

Спосіб одержання сульфаілзаміщаних похідних фенетіламіна, а також їх кислотно-адитивних солей

Info

Publication number
UA5980A1
UA5980A1 UA3245545A UA3245545A UA5980A1 UA 5980 A1 UA5980 A1 UA 5980A1 UA 3245545 A UA3245545 A UA 3245545A UA 3245545 A UA3245545 A UA 3245545A UA 5980 A1 UA5980 A1 UA 5980A1
Authority
UA
Ukraine
Prior art keywords
producing
acid additive
additive salts
phenethylamine derivatives
substituted phenethylamine
Prior art date
Application number
UA3245545A
Other languages
English (en)
Russian (ru)
Inventor
Імаї Казуо
Hіїгата Куніхіро
Фудзікура Такасі
Хасімото Сінаті
Такєнака Тоіті
Original Assignee
Ямануті Фармасьютікал Ко., Лтд
Яманути Фармасьютикал Ко., Лтд
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11859488&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA5980(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ямануті Фармасьютікал Ко., Лтд, Яманути Фармасьютикал Ко., Лтд filed Critical Ямануті Фармасьютікал Ко., Лтд
Publication of UA5980A1 publication Critical patent/UA5980A1/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D203/00—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D203/04—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D203/06—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D203/08—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom
    • C07D203/10—Radicals substituted by singly bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Предметом винаходу є спосіб одержання сульфамоїлзаміщених похідних фенетиламіну, а також їхніх кислотно-адитивних солей. Сполуку певної формули піддають взаємодії з галоїдувальним агентом в середовищі органічного розчинника, а потім при необхідності отриманий при цьому галоїдований продукт відновлюється воднем у присутності каталізатора в середовищі органічного розчинника.
UA3245545A 1980-02-08 1981-02-06 Спосіб одержання сульфаілзаміщаних похідних фенетіламіна, а також їх кислотно-адитивних солей UA5980A1 (uk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP1438280A JPS56110665A (en) 1980-02-08 1980-02-08 Sulfamoyl-substituted phenetylamine derivative and its preparation

Publications (1)

Publication Number Publication Date
UA5980A1 true UA5980A1 (uk) 1994-12-29

Family

ID=11859488

Family Applications (3)

Application Number Title Priority Date Filing Date
UA3379949A UA5981A1 (uk) 1980-02-08 1981-02-06 Спосіб одержання сульфамоілзаміщеного похідного фенетіламіна і його кислотної солі
UA3245545A UA5980A1 (uk) 1980-02-08 1981-02-06 Спосіб одержання сульфаілзаміщаних похідних фенетіламіна, а також їх кислотно-адитивних солей
UA3382004A UA5990A1 (uk) 1980-02-08 1981-02-06 Спосіб одержання сульфамоілзаміщених похідних фенетіламіна або його солянокислої солі

Family Applications Before (1)

Application Number Title Priority Date Filing Date
UA3379949A UA5981A1 (uk) 1980-02-08 1981-02-06 Спосіб одержання сульфамоілзаміщеного похідного фенетіламіна і його кислотної солі

Family Applications After (1)

Application Number Title Priority Date Filing Date
UA3382004A UA5990A1 (uk) 1980-02-08 1981-02-06 Спосіб одержання сульфамоілзаміщених похідних фенетіламіна або його солянокислої солі

Country Status (17)

Country Link
US (6) US4373106A (uk)
EP (1) EP0034432B1 (uk)
JP (1) JPS56110665A (uk)
AR (2) AR227533A1 (uk)
AT (1) ATE7223T1 (uk)
AU (1) AU541720B2 (uk)
CA (1) CA1177849A (uk)
DE (2) DE19675042I2 (uk)
ES (1) ES499224A0 (uk)
GR (1) GR73827B (uk)
IE (1) IE50862B1 (uk)
LU (1) LU90000I2 (uk)
MX (2) MX6859E (uk)
NL (1) NL950014I2 (uk)
PT (1) PT72460B (uk)
SU (3) SU1082320A3 (uk)
UA (3) UA5981A1 (uk)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5391825A (en) * 1980-02-08 1995-02-21 Yamanouchi Pharmaceutical Co., Ltd. Sulfamoyl substituted phenethylamine intermediates
JPS56110665A (en) * 1980-02-08 1981-09-01 Yamanouchi Pharmaceut Co Ltd Sulfamoyl-substituted phenetylamine derivative and its preparation
EP0091749A3 (en) * 1982-04-08 1984-12-05 Beecham Group Plc Ethanolamine derivatives, process for their preparation and pharmaceutical compositions containing them
US4772475A (en) * 1985-03-08 1988-09-20 Yamanouchi Pharmaceutical Co., Ltd. Controlled-release multiple units pharmaceutical formulation
JPS62114952A (ja) * 1985-11-13 1987-05-26 Yamanouchi Pharmaceut Co Ltd 置換フエネチルアミン誘導体の製造法
JPH066565B2 (ja) * 1986-07-21 1994-01-26 山之内製薬株式会社 光学活性なベンゼンスルホンアミド誘導体の製造法
US4971990A (en) * 1988-02-19 1990-11-20 Hokuriku Pharmaceutical Co., Ltd. Phenoxyethylamine derivatives, for preparing the same and composition for exhibiting excellent α1 -blocking activity containing the same
IE64061B1 (en) * 1989-09-04 1995-07-12 Yamanouchi Pharma Co Ltd External preparation containing amusulosin
US5288759A (en) * 1992-08-27 1994-02-22 Alcon Laboratories, Inc. Use of certain sulfamoyl-substituted phenethylamine derivatives to reverse drug-induced mydriasis
AU7085194A (en) * 1993-07-14 1995-02-13 Yamanouchi Pharmaceutical Co., Ltd. Remedy for urination disorder accompanying prostatic hypertrophy
FR2737494B1 (fr) * 1995-08-04 1997-08-29 Synthelabo Derives de benzenesulfonamide, leur preparation et leur application en therapeutique
US6177430B1 (en) 1997-03-27 2001-01-23 Pfizer Inc Use of α1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
WO1997038593A1 (en) * 1996-04-12 1997-10-23 Beth Israel Deaconess Medical Center, Inc. Diabetic supplement bar
US6410554B1 (en) 1998-03-23 2002-06-25 Merck & Co., Inc. Combination therapy for the treatment of benign prostatic hyperplasia
MXPA00010805A (es) * 1998-05-06 2002-05-08 Univ Duke Metodo para el tratamiento de sindromes de la vejiga y del tracto urinario inferior.
TW536402B (en) 1998-06-26 2003-06-11 Yamanouchi Pharma Co Ltd Pharmaceutical composition for the therapy of voiding dysfunction
EP1118322A4 (en) 1998-09-30 2004-10-20 Takeda Chemical Industries Ltd MEDICINES FOR IMPROVING BUBBLE EMPTYING STRENGTH
AR022348A1 (es) * 1999-08-09 2002-09-04 Astellas Pharma Inc Una composicion farmaceutica para el tratamiento de los sintomas del tracto urinario inferior
IL141235A (en) * 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
US20020035107A1 (en) 2000-06-20 2002-03-21 Stefan Henke Highly concentrated stable meloxicam solutions
US20020065286A1 (en) * 2000-08-21 2002-05-30 Davies Michael John Treatment of wounds
US20020091129A1 (en) * 2000-11-20 2002-07-11 Mitradev Boolell Treatment of premature ejaculation
JP2001288115A (ja) * 2001-02-07 2001-10-16 Yamanouchi Pharmaceut Co Ltd 下部尿路症治療剤
KR100421508B1 (ko) * 2001-08-07 2004-03-09 김정한 항균 및 항진균 활성을 갖는 신규한 펜에틸아민 유도체와이의 염
US6835853B2 (en) 2001-10-31 2004-12-28 Synthon Bv Process for resolution of tamsulosin and compounds, compositions, and processes associated therewith
WO2003039530A1 (en) * 2001-11-07 2003-05-15 Synthon B.V. Tamsulosin tablets
DE10161077A1 (de) 2001-12-12 2003-06-18 Boehringer Ingelheim Vetmed Hochkonzentrierte stabile Meloxicamlösungen zur nadellosen Injektion
US20030229001A1 (en) * 2002-01-31 2003-12-11 Pfizer Inc. Treatment of male sexual dysfunction
EP1490090A4 (en) 2002-02-22 2006-09-20 New River Pharmaceuticals Inc SYSTEMS FOR DELIVERING ACTIVE AGENTS AND METHODS FOR PROTECTING AND DELIVERING ACTIVE AGENTS
BR0309435A (pt) 2002-04-24 2005-02-15 Boehringer Ingelheim Pharma Combinação farmacêutica para o tratamento de hiperplasia prostática benigna ou para a prevenção a longo prazo de retenção urinária aguda
US6894188B1 (en) * 2002-04-30 2005-05-17 Ranbaxy Laboratory Limited Tamsulosin derivative
ES2200699B1 (es) * 2002-07-12 2005-10-01 Ragactives, S.L Procedimiento para la separacion de r(-) y s(+)-5-(2-((2-(etoxifenoxi)etil)amino)propil-2-metoxibenceno-sulfonamida.
WO2004016582A1 (en) * 2002-08-14 2004-02-26 Natco Pharma Limited An improved process for the preparation of tamsulosin hydrochloride
ATE502635T1 (de) 2002-08-19 2011-04-15 Pfizer Kombinationstherapie gegen hyperproliferative erkrankungen
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
US8992980B2 (en) 2002-10-25 2015-03-31 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
US7018658B2 (en) 2002-11-14 2006-03-28 Synthon Bv Pharmaceutical pellets comprising tamsulosin
US7323462B2 (en) * 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
CA2509605C (en) 2002-12-13 2010-10-05 Warner-Lambert Company Llc Alpha-2-delta ligand to treat lower urinary tract symptoms
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
SI1603866T1 (sl) * 2002-12-26 2009-08-31 Cadila Healthcare Ltd Postopek za pripravo enantiomerno ÄŤistega (R)-ali (S)-5-(2-aminopropil)-2-metoksibenzensulfonamida
KR100503639B1 (ko) 2003-02-12 2005-07-26 보령제약 주식회사 탐술로신의 정제 방법
PA8597401A1 (es) * 2003-03-14 2005-05-24 Pfizer Derivados del acido 3-(1-[3-(1,3-benzotiazol-6-il) propilcarbamoil] cicloalquil) propanoico como inhibidores de nep
DE10315702A1 (de) * 2003-04-07 2004-10-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Arzneitmittelkombinationen zur Behandlung von gutartiger Prostatahyperplasie oder zur Behandlung von abakterieller Prostatitis
US20040220186A1 (en) * 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
CA2753318A1 (en) * 2003-05-30 2004-12-09 Ranbaxy Laboratories Limited Substituted pyrrole derivatives
US20050065158A1 (en) * 2003-07-16 2005-03-24 Pfizer Inc. Treatment of sexual dysfunction
US7291640B2 (en) * 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
US20050106253A1 (en) * 2003-11-13 2005-05-19 Platteeuw Johannes J. Pharmaceutical pellets comprising tamsulosin
CA2451175A1 (en) * 2003-11-26 2005-05-26 Torcan Chemical Ltd. Process for the preparation of tamsulosin
KR100596373B1 (ko) * 2003-12-09 2006-07-04 씨제이 주식회사 광학적으로 순수한 펜에틸 아민 유도체의 제조방법
SI21656A (sl) * 2003-12-29 2005-06-30 LEK farmacevtska družba d.d. Priprava (R)-5-(2-(2-(2-etoksifenoksi) etilamino)-1-propil)-2-metoksibenzensulfonamida hidroklorida z visoko kemijsko čistoto
SI21655A (sl) * 2003-12-29 2005-06-30 LEK farmacevtska dru�ba d.d. Sinteza optično čistega (R)-5-(2-aminopropil)-2-metoksibenzensulfonamida
EP1568369A1 (en) 2004-02-23 2005-08-31 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the treatment of respiratory diseases in pigs
US20050267096A1 (en) * 2004-05-26 2005-12-01 Pfizer Inc New indazole and indolone derivatives and their use pharmaceuticals
US20050288270A1 (en) * 2004-05-27 2005-12-29 Pfizer Inc New aminopyridine derivatives and their use as pharmaceuticals
JP4800213B2 (ja) * 2004-07-07 2011-10-26 浜理薬品工業株式会社 光学活性フェニルプロピルアミン誘導体の製法
CN100545148C (zh) 2004-08-16 2009-09-30 神隆新加坡私人有限公司 一种抗良性前列腺肥大药物坦索罗辛之合成方法
US7238839B2 (en) 2004-10-07 2007-07-03 Divi's Laboratories Limited Process for the resolution of racemic (R,S) -5-(2-(2-(2- ethoxyphenoxy) ethylamino)Propyl)-2-methoxybenzene sulfonamide (tamsulosin), its novel R and S isomers and their salts and processes for their preparation
PT103216B (pt) 2004-12-06 2010-05-19 Hovione Farmaciencia S A Preparação de tamsulosin
WO2006065555A2 (en) * 2004-12-13 2006-06-22 Boehringer Ingelheim Pharmaceuticals, Inc. Use of alpha-adrenergic blockers for the treatment of dysmenorrhea
ES2258394B1 (es) * 2004-12-31 2007-12-01 Quimica Sintetica, S.A. Procedimiento enzimatico para la preparacion de un compuesto intermedio y su uso en la sintesis de tamsulosina clorhidrato.
WO2006100588A1 (en) * 2005-03-21 2006-09-28 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
DE602006003416D1 (de) * 2005-03-21 2008-12-11 Pfizer Ltd Substituierte triazolderivate als oxytocinantagonisten
CA2607809A1 (en) * 2005-05-04 2007-01-11 Medichem, S.A. Process for the preparation of tamsulosin
WO2006134212A2 (en) * 2005-06-15 2006-12-21 Fermion Oy Preparation of tamsulosin hydrochloride from tamsulosi
EP1917257A1 (en) * 2005-08-10 2008-05-07 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
WO2007031823A1 (en) * 2005-09-12 2007-03-22 Aurobindo Pharma Limited An improved process for preparing tamsulosin hydrochloride
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
SG166829A1 (en) * 2005-11-08 2010-12-29 Ranbaxy Lab Ltd Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7919506B2 (en) 2006-03-10 2011-04-05 Pfizer Inc. Dibenzyl amine compounds and derivatives
US8383660B2 (en) 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives
US20070238716A1 (en) * 2006-03-14 2007-10-11 Murthy Ayanampudi S R Statin stabilizing dosage formulations
WO2007131804A1 (en) 2006-05-17 2007-11-22 Synthon B.V. Tablet composition with a prolonged release of tamsulosin
WO2008010087A2 (en) * 2006-07-14 2008-01-24 Ranbaxy Laboratories Limited Polymorphic forms of an hmg-coa reductase inhibitor and uses thereof
EP2049117A4 (en) * 2006-08-08 2010-08-25 Auspex Pharmaceuticals Inc PREPARATION AND USE OF SUBSTITUTED CHINAZOLIN COMPOUNDS WITH ALPHA-ADRENERGER BLOKING EFFECT
US20080113030A1 (en) * 2006-11-09 2008-05-15 Ching-Fen Hsiao Sustained release tamsulosin formulations
CN101190890B (zh) * 2006-11-30 2011-04-27 江苏豪森药业股份有限公司 5-[(2r)-[2-[2-[2-(2,2,2-三氟乙氧基)苯氧基]乙基]氨基]丙基]-2-甲氧基苯磺酰胺
ES2382009T3 (es) 2006-12-01 2012-06-04 Bristol-Myers Squibb Company Derivados de N-((3-bencil)-2,2-(bis-fenil-)-propan-1-amina como inhibidores de CETP para el tratamiento de aterosclerosis y enfermedades cardiovasculares
US20080312328A1 (en) * 2007-06-14 2008-12-18 Protia, Llc Deuterium-enriched tamsulosin
US20090004284A1 (en) * 2007-06-26 2009-01-01 Watson Pharmaceuticals, Inc. Controlled release tamsulosin hydrochloride formulation
CA2697137A1 (en) * 2007-07-20 2009-01-29 Astellas Pharma Inc. Pharmaceutical composition for amelioration of lower urinary tract symptoms associated with prostatomegaly
CA2709727A1 (en) 2007-12-21 2009-07-02 Astellas Pharma Inc. Pharmaceutical composition for improving lower urinary tract symptoms
EP2181707A1 (en) 2008-11-04 2010-05-05 Astellas Ireland Co., Ltd. Combined use of an alpha-adrenergic receptor antagonist and an anti-muscarinic agent
US8465770B2 (en) 2008-12-24 2013-06-18 Synthon Bv Low dose controlled release tablet
EP2394648B1 (en) 2009-02-04 2016-08-31 Astellas Pharma Inc. Pharmaceutical composition for oral administration
EP2255793A1 (en) 2009-05-28 2010-12-01 Krka Tovarna Zdravil, D.D., Novo Mesto Pharmaceutical composition comprising tamsulosin
EP4378443A2 (en) 2009-10-12 2024-06-05 Boehringer Ingelheim Vetmedica GmbH Containers for compositions comprising meloxicam
CN102050766B (zh) * 2009-11-03 2013-08-07 安徽省新星药物开发有限责任公司 一种盐酸氨磺洛尔的合成方法
US9149480B2 (en) 2010-03-03 2015-10-06 Boehringer Ingeleheim Vetmedica GmbH Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats
US9795568B2 (en) 2010-05-05 2017-10-24 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets
WO2012110092A1 (en) 2011-02-17 2012-08-23 Synthon Bv Tamsulosin derivatives
AU2014255381A1 (en) 2013-04-17 2015-10-08 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
BR102013020508B1 (pt) 2013-08-12 2021-01-12 Ems S/A. Forma de dosagem que compreende um inibidor de esteroide 5-alfa-redutase e um bloqueador alfa, processo para a preparaçãode uma forma de dosagem e uso da forma de dosagem
ES2555485T1 (es) 2014-05-26 2016-01-04 Galenicum Health S.L. Composiciones farmacéuticas que contienen un agente activo
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
CN106478467B (zh) * 2016-10-13 2018-07-13 深圳万和制药有限公司 制备稳定的盐酸坦索罗辛的方法
WO2019076966A1 (en) 2017-10-17 2019-04-25 Synthon B.V. TABLETS COMPRISING TAMSULOSIN AND SOLIFENACIN
EP3473244A1 (en) 2017-10-20 2019-04-24 Veru Inc. Controlled release oral tamsulosin hydrochloride
EP3473245A1 (en) 2017-10-20 2019-04-24 Veru Inc. Controlled release oral tamsulosin hydrochloride
CN108037196B (zh) * 2017-11-23 2020-06-23 中山奕安泰医药科技有限公司 一种3-硝基-4-[[(四氢-2h-吡喃-4-基)甲基]氨基]苯磺酰胺的检测方法
EP3911648A4 (en) 2019-01-18 2022-10-26 Astrazeneca AB PCSK9 INHIBITORS AND METHODS OF USE THEREOF

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3701808A (en) * 1967-12-21 1972-10-31 Allen & Hanburys Ltd Phenylethanolamines
ES373606A1 (es) * 1968-11-18 1972-06-01 Pfizer Un procedimiento para la preparacion de nuevos derivados depropanolamina.
US3878212A (en) * 1970-04-28 1975-04-15 Clemens Rufer Blood sugar lowering sulfamoyl pyrimidines and asymmetrical carbon atom
US4137328A (en) * 1970-07-18 1979-01-30 Pfizer Inc. Phenyl-alkanolamine, alkylamine and α-aminoalkyl ketone derivatives as heart stimulants
US3711545A (en) * 1971-02-23 1973-01-16 Smith Kline French Lab Alpha-aminoalkyl-4-hydroxy-3-sulfamoylaminobenzyl alcohols
DE2115926C3 (de) * 1971-04-01 1978-05-03 C.H. Boehringer Sohn, 6507 Ingelheim 1 -(4-Hydroxy-3-dimethylaminosuIfamidophenyI)-2-aminoäthanderivate, Verfahren zu ihrer Herstellung und diese enthaltende Mittel
US3860647A (en) * 1973-08-20 1975-01-14 Smithkline Corp {60 -Aminomethyl-4-hydroxy-3-sulfamyl-benzyl alcohols and 4-hydroxy-3-sulfamyl phenethylamines
GB1593651A (en) * 1977-02-03 1981-07-22 Allen & Hanburys Ltd Amides
CA1147342A (en) * 1977-10-12 1983-05-31 Kazuo Imai Process of producing novel phenylethanolamine derivatives
JPS5553261A (en) * 1978-10-17 1980-04-18 Yamanouchi Pharmaceut Co Ltd New phenylethanolamine derivative and its preparation
JPS5553262A (en) * 1978-10-17 1980-04-18 Yamanouchi Pharmaceut Co Ltd Phenylethanolamine derivative
JPS606330B2 (ja) * 1978-11-30 1985-02-18 山之内製薬株式会社 α・β両遮断剤
JPS56110665A (en) * 1980-02-08 1981-09-01 Yamanouchi Pharmaceut Co Ltd Sulfamoyl-substituted phenetylamine derivative and its preparation
US4558156A (en) * 1980-02-08 1985-12-10 Yamanouchi Pharmaceutical Co., Ltd. Sulfamoyl-substituted phenethylamine derivatives
DE3110573A1 (de) * 1981-03-18 1982-10-21 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von n- und o-substituierten di- und/oder polyurethanen
JPS5950671B2 (ja) * 1982-08-26 1984-12-10 山之内製薬株式会社 フェニルエタノ−ルアミン誘導体およびその製造法
US4558106A (en) * 1983-03-29 1985-12-10 Union Carbide Corporation Polymerization process using metal formate to reduce the color of thermoplastic copolymers

Also Published As

Publication number Publication date
ES8201966A1 (es) 1982-01-01
US4731478A (en) 1988-03-15
US4987152A (en) 1991-01-22
AU6689681A (en) 1981-08-13
IE810236L (en) 1981-08-08
SU1248533A3 (ru) 1986-07-30
US4761500A (en) 1988-08-02
PT72460B (en) 1982-02-04
EP0034432A2 (en) 1981-08-26
EP0034432A3 (en) 1982-03-24
GR73827B (uk) 1984-05-04
US4373106A (en) 1983-02-08
AR227533A1 (es) 1982-11-15
IE50862B1 (en) 1986-08-06
AU541720B2 (en) 1985-01-17
US4703063A (en) 1987-10-27
SU1082320A3 (ru) 1984-03-23
JPS56110665A (en) 1981-09-01
CA1177849A (en) 1984-11-13
ATE7223T1 (de) 1984-05-15
ES499224A0 (es) 1982-01-01
SU1181540A3 (ru) 1985-09-23
PT72460A (en) 1981-03-01
UA5990A1 (uk) 1994-12-29
US4868216A (en) 1989-09-19
MX9203592A (es) 1992-07-31
DE3163257D1 (en) 1984-05-30
AR230433A1 (es) 1984-04-30
JPS6252742B2 (uk) 1987-11-06
NL950014I1 (nl) 1996-12-02
EP0034432B1 (en) 1984-04-25
DE19675042I2 (de) 2001-06-13
UA5981A1 (uk) 1994-12-29
LU90000I2 (fr) 1997-03-04
NL950014I2 (nl) 1997-01-06
MX6859E (es) 1986-09-08

Similar Documents

Publication Publication Date Title
UA5980A1 (uk) Спосіб одержання сульфаілзаміщаних похідних фенетіламіна, а також їх кислотно-адитивних солей
ATE18863T1 (de) Verfahren zur herstellung freifliessender ethyl- cellulose-mikrokapseln.
GB1459571A (en) Thiophene-2-sulphonamide derivatives and their use as therapeutic agents sheet orienting apparatus
ES381961A1 (es) Procedimiento de preparacion de nuevos derivados de acido fenilacetico, racemicos u opticamente activos.
GB1477945A (en) Method of protecting polyurethane resins from degradation by ultra violet radiation
ES417099A1 (es) Procedimiento de fabricacion de nuevos agentes oxidantes y secuestrantes.
GB1320032A (en) Imidazole derivatives
ES481264A1 (es) Procedimiento para fabricar derivados del acido arilacetico.
ES466127A1 (es) Un procedimiento para la preparacion de l-formil-indol-dihi-droindol dimero.
GB1464067A (en) Process for preparing hydroxyphenol ethers
KR850002956A (ko) 불화탄소 화합물의 정제법
GB1502275A (en) Naphthoquinone derivatives
IE791930L (en) Cyclohexadienes.
KR840005072A (ko) 할로겐화된 아닐린류의 제조방법
JPS537640A (en) Synthesis of diphenylamine derivatives
ES456325A1 (es) Un procedimiento para la preparacion de nuevos derivados delacido 4-hidroxi-2-quinolinon-3-carboxilico.
CH614940A5 (en) Process for the preparation of new terpenoaromatic amidines
ES377089A1 (es) Procedimiento para la obtencion de derivados de imidazo (2,1-a) isoindol.
JPS54148743A (en) Production of methoclopramide
GB1337263A (en) Production of oxygen-containing heterocyclic compounds
JPS5490160A (en) Alpha,alpha-disubstituted-benzylcyanide derivatives
HUT38635A (en) Process for preparing 2,9-dimethyl-4,7-diphenyl-1,10-phenantroline
KR850001259A (ko) 벤즈 안트론의 제조방법
BG60208B2 (en) Process for preparingn-substituted 3-acyl-2-oxindole-1-carboxamides
ES420456A1 (es) Un metodo para la produccion de derivados de benzodiazoci- na.